<DOC>
	<DOCNO>NCT00948857</DOCNO>
	<brief_summary>The experimental focus project interaction DHEA treatment pregnancy woman open tube , fertile male partner evidence premature ovarian failure .</brief_summary>
	<brief_title>Dehydroepiandrosterone ( DHEA ) Treatment Premature Ovarian Failure ( POF )</brief_title>
	<detailed_description>Recruitment : - New patient present Donor egg cycle - Possible print , magazine Radio advertisement Experimental plan : 1 . Informed consent 2 . Baseline study - Antral follicle count - Serum FSH , LH , E2 , Prog , DHEA , DHEAS , testosterone , AMH , Fragile X 3 . Randomization - Group A : DHEA ( 25 mg three time per day ) - Group B : Placebo 4 . Monitoring treatment - All participant : - USG follicle measurement - Repeat serum , FSH , E2 , DHEA , DHEAS , testosterone , AMH monthly treatment . - Physical examination - Completion study questionnaire regard possible androgen effect treatment 5 . Analysis plan : - Primary Outcome - Pregnancy - Pregnancy rate compare use logistic regression age pre-treatment AMH covariates . - Secondary Outcomes - Endocrine Factors - Androgen side effect - Primary analysis . We perform factorial ANOVA two pretreatment factor DHEA Placebo . Baseline AMH age main covariates - Secondary analysis . - Examine rate change estradiol endocrine response four cycle treatment - Compare antral follicle count across cycle group - Compare possible androgen relate effect - Power consideration : - Power assumption : alpha 0.05 ; 80 % power Spontaneous Pregnancy rate POF le 1 % per 3 month Intervention improve pregnancy rate 10 % per 3 month . Patients treat 3 cycle . Require 100 patient complete treatment group . Allow 20 % dropout need 120 patient randomize group - Randomization : Randomization permute block order maintain even distribution among group ( small number participant ) - Human subject issue - Potential risk associate DHEA use - Potential risk delay treatment 3 month possible natural continue loss fertility - Informed consent issue</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Menopause , Premature</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>&gt; = 1 year infertility &gt; 21 &lt; 40 year old Normal HSG Normal Semen analysis ( Count &gt; = 20 million/ motility &gt; 50 % / Kruger morph &gt; 14 % . Absent menses Willingness sign inform consent study randomization Willingness participate 3 month treatment . Abnormal semen analysis Abnormal HSG Medical condition would contraindicate pregnancy , ovulation induction general anesthesia Family history significant genetic disease , factor V leiden thrombophilia Inability present monitoring visit Inability follow medication instruction Desire undergo fertility treatment complete three month trial</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>DHEA</keyword>
	<keyword>POF</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Ovarian Failure</keyword>
	<keyword>Otherwise Unexplained infertility</keyword>
	<keyword>Ovarian age</keyword>
</DOC>